Scapa Healthcare Signs Technology Licensing Agreement with Synedgen for Wound Care Technology
Under the terms of the agreement, Scapa Healthcare has exclusive rights over Synedgen’s glycopolymer technology in the field of dermal wounds and surgical care applications.
Scapa Healthcare, an SWM International business, and Synedgen Inc. recently announced that they have signed an exclusive worldwide licensing agreement for two wound care treatments developed using Synedgen’s proprietary glycochemistry technology platform. The agreement also gives Scapa Healthcare the right to use Synedgen’s glycopolymer technology in conjunction with other wound care technologies. Under the terms of the agreement, Scapa Healthcare has exclusive rights over Synedgen’s glycopolymer technology in the field of dermal wounds and surgical care applications, both over the counter and in the professional setting.
The advanced glycopolymer-based wound cleanser and wound hydrogel formulae control infection and promote wound healing by limiting bacterial infection, disrupting mature biofilm, and reducing inflammation and scarring of acute and chronic wounds and surgical incisions. Developed with support from the Defense Health Agency (DHA) and the Defense Advanced Research Projects Agency (DARPA), these wound care products are FDA 510(k) cleared. In addition to the two market-ready products, this technology reportedly offers a wide range of possibilities for customized wound management solutions in combination with other advanced wound care technologies, including hydrocolloids, hydrogels, collagen, and medical foam materials.